logo

For the Inventor, By the Inventor

Athlone, Ireland

Edward J Geoghegan

USPTO Granted Patents = 20

Average Co-Inventor Count = 2.5

ph-index = 17

Forward Citations = 1,926(Granted Patents)


Location History:

  • Westmeath, IE (1989 - 1994)
  • Athlone, IE (1987 - 2003)

Company Filing History:

goldMedal15 out of 67 
 
Elan Corporation, Plc
 patents
silverMedal2 out of 3 
 
Elan Transdermal Limited
 patents
bronzeMedal1 out of 1 
 
501 Elan Corporation Plc.
 patent
4. 1 out of 1 
 
Eland Corporation P.l.c.
 patent
5. 1 out of 2 
 
Athpharma Limited
 patents

Years Active: 1987-2003

Loading Chart...
20 patents (USPTO):Explore Patents
1. 6641839 - Pharmaceutical formulations for preventing drug tolerance (2003-11-04),
2. 5616345 - Controlled absorption diltiazen formulation for once-daily administration (1997-04-01),
3. 5364620 - Controlled absorption diltiazem formulation for once daily administration (1994-11-15),
4. 5354556 - Controlled release powder and process for its preparation (1994-10-11),
5. 5336504 - Diltiazem formulations and methods of treatment (1994-08-09),
6. 5298257 - Method for the treatment of withdrawal symptoms associated with smoking (1994-03-29),
7. 5219621 - Methods of treatment with diltiazem formulations (1993-06-15),
8. 5002776 - Controlled absorption diltiazem formulations (1991-03-26),
9. 4952402 - Controlled release powder and process for its preparation (1990-08-28),
10. 4946853 - Method for the treatment of withdrawal symptoms associated with smoking (1990-08-07),
11. 4940588 - Controlled release powder and process for its preparation (1990-07-10),
12. 4917899 - Controlled absorption diltiazem formulation (1990-04-17),
13. 4898737 - Controlled absorption pharmaceutical composition (1990-02-06),
14. 4894240 - Controlled absorption diltiazem formulation for once-daily administration (1990-01-16),
15. 4891230 - Diltiazem formulation (1990-01-02),

Title: Edward J Geoghegan: Innovator in Pharmaceutical Formulations

Introduction

Edward J Geoghegan is a renowned inventor based in Athlone, Ireland, with a remarkable portfolio of 20 patents. His innovative work primarily focuses on pharmaceutical formulations that enhance drug efficacy and patient outcomes.

Latest Patents

Geoghegan's most recent patents include groundbreaking formulations aimed at preventing drug tolerance. One notable invention is the formulation for Isosorbide mononitrate which innovatively utilizes subtherapeutic levels during a washout period to mitigate nitrate tolerance. Another significant contribution is a controlled absorption formulation of Diltiazem designed for once-daily administration. This formulation features a core of Diltiazem enclosed by a multi-layer membrane that allows for controlled release over a 24-hour period, ensuring consistent therapeutic levels post-administration.

Career Highlights

Throughout his career, Edward J Geoghegan has made substantial contributions to the pharmaceutical industry, notably through his roles at Elan Corporation Plc and Elan Transdermal Limited. His work has consistently been at the forefront of drug formulation technologies, significantly impacting how medications are administered and absorbed.

Collaborations

Geoghegan has collaborated with several esteemed professionals in the field, including Donald E Panoz and Seamus Mulligan. These collaborations have further strengthened the innovative landscape of pharmaceutical developments, enhancing the effectiveness of treatments and improving patient care.

Conclusion

Edward J Geoghegan's contributions to the field of pharmaceutical formulations are marked by his numerous patents and collaborations. His pioneering approaches in drug formulation continue to offer significant advancements in preventing drug tolerance and improving medication administration.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…